Literature DB >> 17037976

The multiple endocrine neoplasia syndromes.

Vipul T Lakhani1, Y Nancy You, Samuel A Wells.   

Abstract

Multiple endocrine neoplasia (MEN) type 1 and type 2 exhibit an autosomal dominant pattern of inheritance. In the past two decades the germline mutations that cause these inherited syndromes have been identified. The large majority of patients with MEN1 have mutations in the menin gene. Mutations in the REarranged during Transfection (RET) gene cause MEN2A, MEN2B, and familial medullary thyroid carcinoma (FMTC). Specific codon mutations within RET correlate with disease phenotype and severity. Also, children from families with MEN2A, MEN2B, or FMTC, who are found to have inherited a mutated RET allele, can be managed by prophylactic thyroidectomy, thus preventing the development of medullary thyroid carcinoma (MTC), the dominant endocrinopathy in patients with these hereditary syndromes. New insights into the molecular pathway of RET signal transduction are leading to novel targeted therapies in patients with locally advanced or metastatic hereditary MTC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17037976     DOI: 10.1146/annurev.med.58.100305.115303

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  20 in total

Review 1.  Targeted medical therapy of biliary tract cancer: recent advances and future perspectives.

Authors:  Michael Hopfner; Detlef Schuppan; Hans Scherubl
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

Review 2.  Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.

Authors:  Michael Höpfner; Detlef Schuppan; Hans Scherübl
Journal:  World J Gastroenterol       Date:  2008-04-28       Impact factor: 5.742

Review 3.  Multiple endocrine neoplasia syndromes associated with mutation of p27.

Authors:  M Lee; N S Pellegata
Journal:  J Endocrinol Invest       Date:  2013-06-26       Impact factor: 4.256

Review 4.  Oral Manifestations and Molecular Basis of Oral Genodermatoses: A Review.

Authors:  Kiran Kumar; A S Shilpasree; Meenakshi Chaudhary
Journal:  J Clin Diagn Res       Date:  2016-05-01

5.  Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer.

Authors:  Lars Bastholt; Michael C Kreissl; Dagmar Führer; Ana L Maia; Laura D Locati; Léa Maciel; Yi Wu; Kevin N Heller; Alan Webster; Rossella Elisei
Journal:  Eur Thyroid J       Date:  2016-09-10

6.  Orolabial signs are important clues for diagnosis of the rare endocrine syndrome MEN 2B. Presentation of two unrelated cases.

Authors:  Agnes Sallai; Eva Hosszú; Péter Gergics; Károly Rácz; György Fekete
Journal:  Eur J Pediatr       Date:  2007-06-19       Impact factor: 3.183

7.  American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment.

Authors:  Robin T Zon; Elizabeth Goss; Victor G Vogel; Rowan T Chlebowski; Ismail Jatoi; Mark E Robson; Dana S Wollins; Judy E Garber; Powel Brown; Barnett S Kramer
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

8.  Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations.

Authors:  Bella Kaufman; Yael Laitman; Jacek Gronwald; Robert Winqvist; Arvids Irmejs; Jan Lubinski; Katri Pylkäs; Janis Gardovskis; Edvins Miklasevics; Eitan Friedman
Journal:  Fam Cancer       Date:  2009-07-17       Impact factor: 2.375

Review 9.  Update: the status of clinical trials with kinase inhibitors in thyroid cancer.

Authors:  Samuel A Wells; Massimo Santoro
Journal:  J Clin Endocrinol Metab       Date:  2014-01-13       Impact factor: 5.958

10.  The structure of the glial cell line-derived neurotrophic factor-coreceptor complex: insights into RET signaling and heparin binding.

Authors:  Vimal Parkash; Veli-Matti Leppänen; Heidi Virtanen; Jaana M Jurvansuu; Maxim M Bespalov; Yulia A Sidorova; Pia Runeberg-Roos; Mart Saarma; Adrian Goldman
Journal:  J Biol Chem       Date:  2008-10-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.